QIAGEN announced the expansion of its digital PCR (dPCR) offering for the development of cell and gene therapies in the biopharma industry.
The company has partnered with Niba Labs to offer customized digital PCR assay design services to biopharma customers and also launched the new CGT Viral Vector Lysis Kit that enables a standardized workflow from cell lysates to absolute and precise quantification of viral titers for multiple serotypes.
The partnership between QIAGEN and Niba Labs will allow QIAcuity customers to use the combined expertise of both companies to develop new custom simplex or multiplex assays for the quantification of nucleic acids and to optimize existing qPCR assays for the use in digital PCR. Niba Labs will evaluate the performance of the assays and validate them within Good Manufacturing Practice (GMP). With their combined products and services, QIAGEN and Niba Labs can help cell and gene therapy developers to overcome potential resource constraints and meet demanding project timelines.
The new CGT Viral Vector Lysis Kit launched for the QIAcuity digital PCR instrument adds to QIAGEN’s rapidly growing digital PCR portfolio for the biopharma industry that includes ten QIAcuity Cell and Gene Therapy (CGT) dPCR Assays for use in adeno-associated virus (AAV) titer quantification and three QIAcuity Residual DNA Quantification Kits for checking carryover of host cell DNA. The new kit provides high repeatability and is capable of determining viral genome titers in single- and multiplex reactions, as well as quantification over a broad dynamic range with high accuracy when combined with the QIAcuity CGT dPCR Assays.
